Core Viewpoint - The announcement highlights a strategic collaboration between Heptares Therapeutics-B (02142.HK) and Bristol-Myers Squibb aimed at discovering and developing next-generation multispecific antibodies, with significant financial implications for Heptares [1] Group 1: Partnership Details - Heptares Therapeutics has entered into a long-term global strategic collaboration and licensing agreement with Bristol-Myers Squibb [1] - The collaboration focuses on the discovery and acceleration of multispecific antibodies [1] Group 2: Financial Implications - Heptares Therapeutics will receive an upfront payment totaling $90 million [1] - If Bristol-Myers Squibb chooses to advance all potential projects, Heptares could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties [1]
和铂医药-B(02142.HK)与百时美施贵宝订立全球战略合作及授权协议，获9000万美元预付款及最高10.35亿美元里程碑